Enliven Therapeutics Announces Data Update From Phase 1 Clinical Trial Of ELVN-001 In Chronic Myeloid Leukemia; Reported Cumulative MMR Rate Of 44% (8/18) By 24 Weeks, With Stable Or Deepening Responses Between Weeks 12 And 24, Which Continues To Compare Favorably To Precedent Phase 1 Trials Of Approved BCR::ABL1 TKIs
Portfolio Pulse from Benzinga Newsdesk
Enliven Therapeutics reported positive Phase 1 trial results for ELVN-001 in treating chronic myeloid leukemia, showing a 44% cumulative MMR rate by 24 weeks. The drug was well-tolerated with no dose reductions, indicating potential as a best-in-class treatment.
September 28, 2024 | 1:42 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Enliven Therapeutics' ELVN-001 shows promising results in Phase 1 trial for CML, with a 44% MMR rate by 24 weeks and good tolerance, suggesting potential as a best-in-class treatment.
The positive Phase 1 trial results for ELVN-001, showing a 44% MMR rate and good tolerance, suggest a strong potential for the drug as a best-in-class treatment for CML. This could lead to increased investor interest and a positive impact on Enliven's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100